Mayo Clinic Laboratories has developed a new direct ethanol biomarker test for alcohol consumption that has a much longer detection window than existing urine tests for alcohol use.
Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.
Mayo Clinic’s Advanced Diagnostics Laboratory researchers are using phage immunoprecipitation sequencing to discover new serological biomarkers for autoimmune diseases.
Together, Mayo Clinic Laboratories and Helix will provide biopharma customers with a full spectrum of testing capabilities and end-to-end laboratory testing support.
The MayoComplete Liquid Biopsy Panel offers a noninvasive alternative to traditional cell-based biopsies. This allow for faster turnaround time and the ability to perform molecular DNA testing in cancer patients where tumor tissue isn’t available.
Mayo Clinic researchers are working on developing vaccines that would deliver therapeutic cancer treatment designed to target an individual’s unique tumor characteristics.
BioPharma Diagnostics is offering a new e-guide titled “Finding the right laboratory partner: Top five qualities to support effective scientific research.”
A new FDA-approved test offered by Mayo Clinic Laboratories is expanding testing options for patients with Alzheimer’s disease.
Mayo Clinic Laboratories has developed an assay that offers enhanced detection of the NPM1 genetic mutation that is present in about 30% of patients with acute myeloid leukemia, or AML.
Mayo Clinic Laboratories offers a new test that builds upon the individual NF155 test to help physicians with early diagnosis and treatment optimization.
Yi Lin, M.D., Ph.D., associate professor of medicine at Mayo Clinic and medical director for the Cellular Therapy Program, led a survey to investigate the scope of this problem, which has not been covered in literature thus far. The findings were published as an abstract at the recent annual meeting of the American Society of Clinical Oncology.
Inflammatory bowel disease (IBD) serology testing at Mayo Clinic Laboratories can help physicians distinguish between an ulcerative colitis diagnosis and a Crohn’s disease diagnosis. Melissa Snyder, Ph.D., explains in a “Test in Focus” episode of the “Answers From the Lab” podcast how the IBDP2 serology panel can make this important distinction after first-line testing has failed.